Royalty Pharma plc (RPRX) trades at a trailing P/E of 26.8, forward P/E of 10.0. Trailing earnings yield is 3.73%, forward earnings yield 10.05%. PEG 1.11. Graham Number is $30.06.
Criteria proven by this page:
Overall SharesGrow Score: 72/100 with 5/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 47.7 | -15.27 | 6.08 | 14.39 | - |
| 2017 | 13.0 | 0.05 | 3.53 | 9.86 | 4.66% |
| 2018 | 11.4 | 0.83 | 3.51 | 8.78 | 5.17% |
| 2019 | 6.7 | 0.10 | 2.58 | 8.69 | 4.69% |
| 2020 | 19.9 | -0.25 | 4.03 | 9.15 | 2.05% |
| 2021 | 26.7 | 1.63 | 2.86 | 7.22 | 1.73% |
| 2022 | 404.1 | -4.33 | 3.08 | 7.74 | 1.93% |
| 2023 | 11.1 | 0.00 | 1.93 | 5.34 | 2.85% |
| 2024 | 13.2 | -0.31 | 1.64 | 5.03 | 3.31% |
| 2025 | 21.6 | 1.04 | 2.58 | 7.02 | 2.27% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $0.93 | $1.88B | $565.91M | 30.1% |
| 2017 | $3.42 | $1.6B | $1.21B | 75.7% |
| 2018 | $3.89 | $1.79B | $1.38B | 76.8% |
| 2019 | $6.42 | $1.81B | $2.35B | 129.4% |
| 2020 | $1.32 | $2.12B | $495.2M | 23.3% |
| 2021 | $1.15 | $2.29B | $478.75M | 20.9% |
| 2022 | $0.10 | $2.24B | $42.83M | 1.9% |
| 2023 | $2.53 | $2.35B | $1.13B | 48.2% |
| 2024 | $1.45 | $2.26B | $859M | 37.9% |
| 2025 | $1.80 | $2.38B | $770.95M | 32.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $4.86 | $4.27 – $5.11 | $3.25B | $3.2B – $3.26B | 4 |
| 2027 | $5.25 | $4.58 – $5.78 | $3.48B | $3.45B – $3.51B | 4 |
| 2028 | $6.08 | $5.95 – $6.22 | $3.97B | $3.97B – $3.97B | 1 |
| 2029 | $7.04 | $6.89 – $7.19 | $4.59B | $4.51B – $4.66B | 1 |
| 2030 | $7.71 | $7.54 – $7.88 | $4.99B | $4.91B – $5.08B | 1 |
